Fatty Acid Nutraceuticals For Enhancing Immune Development In Newborns And T Cell-Based Cancer Therapies

SUMMARY

Nutraceutical approach using specific fatty acids naturally found in human breast milk incorporated into infant formula enhancing immune defense in both neonates and adults

The Unmet Need: Solutions for effectively bridging maternal and infant health and immune development through diet

• The field of immune modulation and nutritional therapy has increasingly recognized that early-life immune development is critical for long-term health outcomes. Advances in immunology have highlighted the importance of proper immune cell activation during infancy, as well as the potential benefits of specific nutrients in supporting this process. However, many infants, particularly those not breastfed, do not receive the naturally balanced nutritional components that bolster immune functions. Moreover, current cancer immunotherapeutic strategies often fall short in effectively mobilizing the body’s inherent immune defenses, underscoring a significant gap in both infant nutrition and advanced immunotherapy.

• Existing approaches to enhancing immune responses face substantial challenges. Infant formulas, even when fortified, fail to mimic the complex array of natural compounds provided by maternal milk, leading to suboptimal immune activation in newborns. In parallel, conventional cancer treatments struggle to harness precise immune signaling pathways, resulting in inconsistent T cell activation and limited therapeutic efficacy. These shortcomings point to the urgent need for innovative strategies that can overcome the deficiencies in natural immune support and improve both early developmental health and targeted cancer interventions.

The proposed solution: Three key fatty acids present in human breast milk that enhance CD8+ T cell function

• The faculty inventor identified specific fatty acids present in human milk that enhance CD8+ T cell function through distinct biochemical pathways. Trans-vaccenic acid (TVA) antagonizes the GPR43 receptor to trigger the cAMP-PKA-CREB signaling cascade, while nervonic acid (NVA), also found in seed and fish oils, acts as a GPR40 agonist to activate a similar pathway. In contrast, cis-11,14-eicosadienoic acid (EDA) works intracellularly via FATP2, independent of G protein-coupled receptors. Early studies in mice fed a TVA-enriched diet have shown improved viral resistance and survival rates, suggesting potential applications in infant nutrition and therapeutic interventions.

• This multi-mechanistic approach using natural compounds with unique molecular interactions to boost immune function. By leveraging fatty acids that operate through both receptor-mediated and intracellular pathways, this strategy offers a novel means to support immune development in newborns and enhance T cell–based cancer therapies. The dual advantage of natural origin and targeted action sets this technology apart, providing promising opportunities to improve clinical outcomes and public health through nutritional and immunotherapeutic innovations.

ADVANTAGES

ADVANTAGES

• Enhances CD8+ T cell functionality to improve immune response in newborns and potentially in cancer immunotherapy

• Offers a promising approach to fortify infant formula with beneficial fatty acids to support early immune development

• Provides a basis for specialized maternal nutrition strategies for pregnant and lactating mothers, especially in developing regions

• Presents a novel pathway for bolstering T cell-based therapies, potentially enhancing the efficacy of treatments like CAR T-cell and checkpoint inhibitors

• Demonstrates safety and efficacy through natural presence in breast milk and distinct biochemical mechanisms, opening up multiple clinical applications

APPLICATIONS

• Infant formula enhancement
• Maternal nutrition supplements
• Cancer immunotherapy